-
Home
- Who we are
- Read, watch, listen
- Pharmacy
- Home Delivery
- Specialty Pharmacy
- Specialty Pharmacy - Patients
- Care Specialists Program
- Education Center
- Hypercholesterolemia
- Solid organ transplant
- Asthma
- Cystic fibrosis
- Hemophilia
- Hepatitis C
- Human Immunodeficiency Virus (HIV)
- Inflammatory bowel disease
- Osteoporosis
- Multiple Sclerosis
- Oncology (cancer)
- Psoriasis and psoriatic arthritis
- Rheumatoid arthritis
- Rights and responsibilities
- Overcome medicine challenges
- Specialty Pharmacy - Providers
- Patient Forms
- Careers
- Contact Us
-
Newsroom Custom Content
- Prime Careers Spotlight
- Prime Careers Spotlight: September 2024
- Prime Careers Spotlight: October 2024
- Prime Careers Spotlight: November 2024
- Prime Careers Spotlight: April 2025
- Prime Careers Spotlight: May 2025
- Prime Careers Spotlight: June 2025
- Prime Careers Spotlight: July 2025
- Publications
- Quarterly Pipeline
- Quarterly Drug Pipeline: July 2024
- Quarterly Drug Pipeline: April 2024
- Quarterly Drug Pipeline: January 2024
- Quarterly Drug Pipeline Template 2.0
- Quarterly Drug Pipeline: October 2024
- Quarterly Drug Pipeline: January 2025
- Quarterly Drug Pipeline: April 2025
- Quarterly Drug Pipeline: July 2025
- Clinical Highlights
- Clinical Highlights: September 2024
- Clinical Highlights: October 2024
- Clinical Highlights: November 2024
- Clinical Highlights: December 2024
- Clinical Highlights: January 2025
- Clinical Highlights: February 2025
- Clinical Highlights: March 2025
- Clinical Highlights: April 2025
- Drug Approvals
- Drug Approvals Monthly Update: August 2024
- Drug Approvals Monthly Update: June 2024
- Drug Approvals Monthly Update: May 2024
- Drug Approvals Monthly Update: April 2024
- Drug Approvals Monthly Update: March 2024
- Drug Approvals Monthly Update: February 2024
- Drug Approvals Monthly Update: January 2024
- Drug Approvals Quarterly Update
- Drug Approvals Monthly Update: September 2024
- Drug Approvals: October 2024
- Drug Approvals: November 2024
- Drug Approvals: December 2024
- Drug Approvals: January 2025
- Drug Approvals: July 2024
- Drug Approvals: February 2025
- Drug Approvals: March 2025
- Drug Approvals: April 2025
- Quarterly Drug Approvals
- Quarterly Drug Approvals: October 2024
- Quarterly Drug Approvals: January 2025
- Quarterly Drug Approvals: April 2025
- Quarterly Drug Approvals: July 2025
- High Cost Therapy Profile
- High-Cost Therapy Profile: August 2024
- High-Cost Therapy Profile: June 2024
- High-Cost Therapy Profile: May
- High-Cost Therapy Profile: April
- High-Cost Therapy Profile: March
- High-Cost Therapy Profile: February
- High-Cost Therapy Profile: January
- High-Cost Therapy Profile: September 2024
- HIGH COST THERAPY PROFILE: OCT 2024
- High Cost Therapy Profile: November 2024
- High Cost Therapy Profile: December 2024
- High Cost Therapy Profile: January 2025
- High Cost Therapy Profile: February 2025
- High-Cost Therapy Profile: March 2025
- High Cost Therapy Profile: April 2025
- High-Cost Therapy Profile: May 2025
- High-Cost Therapy Profile: June 2025
- High-Cost Therapy Profile: July 2025
- Oncology Insights
- Oncology Insights: Transformative treatment for small cell lung cancer
- Oncology Insights: First-in-class bladder cancer therapy and the Bacillus Calmette-Guérin (BCG) shortage
- Oncology Insights: October 2024
- Oncology Insights: December 2024
- Oncology Insights: 2024 Rewind
- Oncology Insights: February 2025
- Oncology Insights: March 2025
- Oncology Insights: April 2025
- Oncology Insights: May 2025
- Oncology Insights: June 2025
- Oncology Insights: July 2025
- FDA Decisions Expected
- FDA Decisions Expected: October 2024
- FDA Decisions Expected November 2024
- FDA Decisions Expected: December 2024
- FDA Decisions Expected: January 2025
- FDA Decisions Expected: February 2025
- FDA Decisions Expected: March 2025
- FDA Decisions Expected: April 2025
- FDA Decisions Expected: May 2025
- FDA Decisions Expected: June 2025
- FDA Decisions Expected: July 2025
- FDA Decisions Expected: August 2025
- Expert Clinical Network Insights
- Expert Clinical Network Insights: June 2024
- Expert Clinical Network Insights: April 2024
- Expert Clinical Network Insights: October 2024
- Expert Clinical Network Insights: December 2024
- Expert Clinical Network Insights: March 2025
- Prime Therapeutics Reports
- Fall 2024 Prime Therapeutics Report
- Spring 2024 Prime Therapeutics Report
- Summer 2024 Prime Therapeutics Report
- Spring 2025 Prime Therapeutics Report
- Summer 2025 Prime Therapeutics Report
- GLP-1
- GLP-1 Pipeline Update: November 2024
- The evolution of GLP-1s
- GLP-1 Pipeline Update: February 2025
- GLP-1 Pipeline Update: May 2025
- Clinical Insights
- 2022 Clinical Insights: Therapeutic Psychedlics: An emerging frontier in mental health
- 2022 Clinical Insights: Virtual reality: An emerging paradigm in healthcare
- Trending Topics & Drug Approvals
- Trending Topics & Drug Approvals: May 2025
- Trending Topics & Drug Approvals: June 2025
- Trending Topics & Drug Approvals: July 2025
- Clinical News
- Clinical News
- Clinical News: August 2024
- Clinical News: June 2024
- Clinical News: May 2024
- Clinical News: April 2024
- Employer Market Insight Reports
- Pharmacy Trend Reports
- 2024 Medical Pharmacy Trend Report
- Medicaid Pharmacy Trend Reports
- Weight management: A holistic journey
- Climate change: An imprint on health
- Virtual reality: An emerging paradigm in health care
- Research
- Media
- Compliance / Legal
- Test Pages
Navigate to
Join our residency program
The ASHP-accredited Prime Therapeutics PGY1 residency program will allow you to build your best career in managed care. You will develop a firsthand understanding of medical and pharmacy benefit integration and strategy, with a focus on specialty drug management. The skills and mindset that you cultivate will allow you to be more efficient, adaptable, and well-rounded, and will help kick-start your career as a pharmacist.


WEBINAR: Register to learn about our Residency Program
Nov. 7 | 6 p.m. CT
Take advantage of a 60-minute webinar that helps you better understand our residency program. The leaders of the program will walk through qualifications, compensation and how you can apply.
Take advantage of a 60-minute webinar that helps you better understand our residency program. The leaders of the program will walk through qualifications, compensation and how you can apply.
Contribute today, lead tomorrow
Residents have the opportunity to
- Gain hands-on experience of specialty and medical drug management from a managed care perspective.
- Be a part of the clinical program innovation team and develop/enhance specialty clinical programs in therapeutic areas such as oncology, hemophilia and rare diseases.
- Consult with health plan clients about specialty and medical drug strategies.
- Develop an in-depth understanding of clinical operations, claims adjudication and pricing.
- Evaluate and balance clinical, financial and government considerations to produce patient-focused and therapeutically complete drug lists (formularies).
- Participate and present at P&T Committee meetings.
- Evaluate opportunities and design utilization management criteria to reduce drug misuse and improve member health outcomes.
- Develop a holistic specialty strategy, which includes management opportunities across both pharmacy and medical benefits.
- Learn about the latest developments in specialty pharmacy and broaden understanding of concepts such as value-based contracting, rebates and other innovative strategies.
- Use and expand your knowledge of strategies across Commercial, Medicare and Medicaid lines of business.
- Present your research at national conferences to senior leaders and industry stakeholders.
- Participate in conducting outreach to patients and providers for clinical programs that impact STAR and HEDIS measures.
Compensation
- $50,000 annual salary
- Paid membership dues to AMCP and ASHP
- Paid travel/hotel/fees for professional meetings (AMCP and/or ASHP)
- Generous benefits package
- Medical and dental insurance
- 80 hours of paid time off
- Paid holidays
- Reimbursement for NAPLEX, MPJE (for home state)
Application requirements
- Application, including CV and three letters of recommendation through the PHORCAS system
- On track to graduate from ACPE-Accredited PharmD program by end of spring semester with a minimum of a 3.0 GPA (or “PASS” if in a Pass/Fail program)
- Must obtain pharmacist license from home state within 90 days of starting residency